1
00:00:02,759 --> 00:00:07,240
Speaker 1: Bloomberg Audio Studios, podcasts, radio news.

2
00:00:08,000 --> 00:00:10,600
Speaker 2: Yeah, I'm sitting down now with the CEO of Eli Lilly,

3
00:00:10,960 --> 00:00:11,520
Speaker 2: Dave Rix.

4
00:00:11,560 --> 00:00:12,880
Speaker 3: It's great to see you in person, Dave.

5
00:00:13,000 --> 00:00:14,080
Speaker 1: Great to be with you, Katie.

6
00:00:14,200 --> 00:00:14,880
Speaker 3: Let's start with.

7
00:00:14,840 --> 00:00:16,919
Speaker 2: The news that you have out this morning, and that

8
00:00:17,040 --> 00:00:20,479
Speaker 2: is that Eli Lilly is buying Scorpion Therapeutics breast cancer

9
00:00:20,520 --> 00:00:23,959
Speaker 2: program for up to two point five billion dollars. And

10
00:00:24,040 --> 00:00:26,920
Speaker 2: I'll start with the basics why this deal and why now?

11
00:00:27,360 --> 00:00:29,480
Speaker 4: Yeah, Well, it fits in really well with what we're

12
00:00:29,520 --> 00:00:31,960
Speaker 4: doing in breast cancer, which is changing the lives for

13
00:00:32,040 --> 00:00:34,400
Speaker 4: so many people who suffer from that condition. Of course,

14
00:00:34,479 --> 00:00:37,120
Speaker 4: Versenio's a our leading product in that space. This is

15
00:00:37,159 --> 00:00:40,760
Speaker 4: a targeted therapy for specific mutation in breast cancer effects

16
00:00:40,840 --> 00:00:43,960
Speaker 4: thirty to forty percent of women with breast cancer, and

17
00:00:44,000 --> 00:00:45,919
Speaker 4: Scorpions developed this program.

18
00:00:45,560 --> 00:00:46,280
Speaker 1: Through phase two.

19
00:00:46,760 --> 00:00:48,800
Speaker 4: It's a big Phase three program to do to get

20
00:00:48,800 --> 00:00:50,920
Speaker 4: this to market, and so it's a great transaction for

21
00:00:50,960 --> 00:00:52,880
Speaker 4: both sides and it adds to what we're doing.

22
00:00:52,880 --> 00:00:54,080
Speaker 1: We also have another.

23
00:00:54,240 --> 00:00:56,720
Speaker 4: Oral medication for breast cancer coming. We read out data

24
00:00:56,760 --> 00:00:59,800
Speaker 4: last year, so a growing cluster of medicines there to

25
00:00:59,800 --> 00:01:03,000
Speaker 4: really help people live longer with breast cancer. It's an

26
00:01:03,000 --> 00:01:05,120
Speaker 4: exciting deal for us, and we're pleased to work with

27
00:01:05,160 --> 00:01:06,360
Speaker 4: Scorpion to bring an in house.

28
00:01:06,640 --> 00:01:09,200
Speaker 2: Yeah, and this deal was really interesting because it's a

29
00:01:09,280 --> 00:01:12,679
Speaker 2: nice reminder that, of course el Lily does more than

30
00:01:12,800 --> 00:01:15,280
Speaker 2: just weight loss. So give us some context on the

31
00:01:15,280 --> 00:01:18,960
Speaker 2: overall portfolio here, how the oncology fits with of course

32
00:01:18,959 --> 00:01:20,280
Speaker 2: the weight loss and everything else.

33
00:01:20,080 --> 00:01:20,440
Speaker 1: That you do.

34
00:01:20,720 --> 00:01:22,920
Speaker 4: Yeah, well, we have four therapeutic areas and of course

35
00:01:22,920 --> 00:01:25,960
Speaker 4: the diabetes and weight loss has been the story all

36
00:01:26,160 --> 00:01:28,759
Speaker 4: last year, and it's exciting because it's growing and big.

37
00:01:28,800 --> 00:01:31,160
Speaker 4: But that's about forty percent of the company. The other

38
00:01:31,240 --> 00:01:34,160
Speaker 4: sixty percent is also doing incredibly well breast cancer. We

39
00:01:34,240 --> 00:01:36,920
Speaker 4: mentioned in oncology here, we have other oncology assets, including

40
00:01:36,959 --> 00:01:40,479
Speaker 4: for hematology that are in the market and doing great.

41
00:01:41,080 --> 00:01:43,760
Speaker 4: Immunology is another important area for us, and products like

42
00:01:43,760 --> 00:01:47,800
Speaker 4: Ebgliss for atopic dermatitis, which just launched in Q four, along.

43
00:01:47,520 --> 00:01:48,760
Speaker 1: With Tolts for psoriasis.

44
00:01:49,120 --> 00:01:53,520
Speaker 4: And then neuroscience Alzheimer's launched last year in the fourth

45
00:01:53,600 --> 00:01:56,680
Speaker 4: quarter and we're ramping that now. So the company's got

46
00:01:56,720 --> 00:01:59,120
Speaker 4: a broad portfolio. We want to work on medicines for

47
00:01:59,560 --> 00:02:02,320
Speaker 4: terrible diseases of all kinds, not just obesity, but of

48
00:02:02,320 --> 00:02:04,960
Speaker 4: course the OBCD story is exciting and broad as well.

49
00:02:05,320 --> 00:02:08,000
Speaker 2: And before we get into some of the specific areas

50
00:02:08,040 --> 00:02:10,040
Speaker 2: there when it comes to M and A, obviously there

51
00:02:10,080 --> 00:02:12,560
Speaker 2: is a ton of optimism as it relates to the

52
00:02:12,680 --> 00:02:15,320
Speaker 2: M and A environment under a second Trump administration.

53
00:02:16,160 --> 00:02:17,800
Speaker 3: What is your M and A strategy?

54
00:02:17,800 --> 00:02:20,720
Speaker 2: Where are there more opportunities for inorganic growth?

55
00:02:20,880 --> 00:02:23,520
Speaker 4: Yeah, well, we've been very consistent and it's working for us.

56
00:02:23,520 --> 00:02:26,800
Speaker 4: The motion for us is to go early and stay

57
00:02:26,800 --> 00:02:29,800
Speaker 4: in our lane basically, so focus on the therapeutic areas

58
00:02:29,800 --> 00:02:32,880
Speaker 4: where we know a lot that makes us a smart buyer,

59
00:02:33,160 --> 00:02:36,320
Speaker 4: and by going early, we take more risk, but do

60
00:02:36,480 --> 00:02:39,919
Speaker 4: smaller deals. I know there's been a lot of talk

61
00:02:40,000 --> 00:02:42,359
Speaker 4: about M and A under the Biden administration and how

62
00:02:42,360 --> 00:02:43,079
Speaker 4: hard it's been.

63
00:02:43,000 --> 00:02:44,399
Speaker 1: But for us, not so much.

64
00:02:44,520 --> 00:02:46,880
Speaker 4: We've done one hundred deals in the last three years,

65
00:02:46,880 --> 00:02:49,400
Speaker 4: that's the most in biopharma, but a lot of them

66
00:02:49,440 --> 00:02:52,360
Speaker 4: are small, below the radar, but it builds that early

67
00:02:52,400 --> 00:02:55,120
Speaker 4: stage pipeline strength for us and Lily maybe in a

68
00:02:55,160 --> 00:02:58,280
Speaker 4: little different position because our near term outlook, maybe our

69
00:02:58,320 --> 00:03:01,240
Speaker 4: midterm outlook is so strong we don't need to plug

70
00:03:01,240 --> 00:03:03,919
Speaker 4: a sales gap. We're just trying to find assets where

71
00:03:03,960 --> 00:03:07,119
Speaker 4: we can add value and create great medicines for patients.

72
00:03:07,720 --> 00:03:09,880
Speaker 4: This deal with scorpions another example of that.

73
00:03:10,160 --> 00:03:12,160
Speaker 2: Yeah, and a great point too about flying under the

74
00:03:12,240 --> 00:03:14,639
Speaker 2: radar there with those bite sized deals.

75
00:03:14,800 --> 00:03:17,120
Speaker 3: Let's get to glp ones. Of course, there is a.

76
00:03:17,000 --> 00:03:21,400
Speaker 2: Lot of anticipation and excitement around your oral weight loss drug.

77
00:03:21,480 --> 00:03:25,160
Speaker 2: Of course there's some forthcomic data and if that trial

78
00:03:25,400 --> 00:03:27,680
Speaker 2: in particular is successful, how long.

79
00:03:27,560 --> 00:03:29,480
Speaker 3: Do you think it would take to get approval here?

80
00:03:29,919 --> 00:03:32,680
Speaker 4: Yeah, so a lot of development's going on in our

81
00:03:32,720 --> 00:03:36,440
Speaker 4: incretin portfolio or forg lepron is the name.

82
00:03:36,240 --> 00:03:39,360
Speaker 1: Of the medicine. Yeah, Yeah, it's hard. I had to

83
00:03:39,360 --> 00:03:41,360
Speaker 1: practice too, and we should.

84
00:03:41,080 --> 00:03:43,640
Speaker 4: Get data before the middle of the year, the first

85
00:03:43,680 --> 00:03:47,080
Speaker 4: set of studies. It's highly anticipated and really important one

86
00:03:47,080 --> 00:03:48,840
Speaker 4: because it's convenient, could be an oral pill.

87
00:03:48,880 --> 00:03:50,560
Speaker 1: Two efficacy point.

88
00:03:50,800 --> 00:03:55,320
Speaker 4: Is it as good as ozepic essentially or semi glue

89
00:03:55,360 --> 00:03:59,800
Speaker 4: tide that's the goal for us, and as tolerable. If

90
00:03:59,840 --> 00:04:02,080
Speaker 4: it is, it could be approved in early twenty six

91
00:04:03,360 --> 00:04:06,240
Speaker 4: And the benefit here is not just the convenience of

92
00:04:06,280 --> 00:04:08,160
Speaker 4: the pill, but the ability to scale it. We all

93
00:04:08,200 --> 00:04:11,720
Speaker 4: know the production systems for injectibles have really been stretched,

94
00:04:12,000 --> 00:04:15,520
Speaker 4: and we continue to build sites and so forth. But

95
00:04:15,640 --> 00:04:18,800
Speaker 4: with the oral technology, we can make more and get

96
00:04:18,800 --> 00:04:20,760
Speaker 4: this medicine to more people around the world.

97
00:04:21,480 --> 00:04:22,280
Speaker 1: And I think that's an.

98
00:04:22,240 --> 00:04:25,040
Speaker 4: Exciting development for the company if the data is positive.

99
00:04:25,080 --> 00:04:26,800
Speaker 2: And I know Mike co Ancher in New York, Matt

100
00:04:26,800 --> 00:04:29,120
Speaker 2: Miller is listening very closely right now. He would tell

101
00:04:29,120 --> 00:04:31,720
Speaker 2: you himself he'd like to get in one of these trials,

102
00:04:31,760 --> 00:04:35,400
Speaker 2: but when he did have them, call me, well, when

103
00:04:35,440 --> 00:04:38,120
Speaker 2: we get to the approval stage, I mean, what do

104
00:04:38,160 --> 00:04:41,200
Speaker 2: you see as the dynamic between the oral medications and

105
00:04:41,279 --> 00:04:43,560
Speaker 2: the injectibles. How much of the market do you see

106
00:04:43,720 --> 00:04:45,520
Speaker 2: the orals potentially taken.

107
00:04:45,839 --> 00:04:47,920
Speaker 4: Well, I think we'll see over the next three years

108
00:04:48,640 --> 00:04:52,839
Speaker 4: fragmentation as you see in any scaled market. Right now,

109
00:04:53,279 --> 00:04:57,880
Speaker 4: total incretins in the world are probably exiting forty to

110
00:04:57,920 --> 00:05:02,120
Speaker 4: fifty billion, and so that's a big market in pharma,

111
00:05:02,320 --> 00:05:04,520
Speaker 4: and it likely is going well north of that, and

112
00:05:04,560 --> 00:05:06,440
Speaker 4: so we'll expect people to carve out niches.

113
00:05:06,440 --> 00:05:07,839
Speaker 1: One niches medicalization.

114
00:05:08,040 --> 00:05:12,160
Speaker 4: So for instance, at the end of last year, zep

115
00:05:12,160 --> 00:05:16,080
Speaker 4: bound or Manjarro showed success in sleep apnea, so here's

116
00:05:16,120 --> 00:05:19,800
Speaker 4: like a targeted condition like ten million Americans, and it's

117
00:05:19,839 --> 00:05:22,320
Speaker 4: the only drug approved in that space, so people with

118
00:05:22,400 --> 00:05:25,279
Speaker 4: that condition will seek the medication. We have also people

119
00:05:25,279 --> 00:05:27,600
Speaker 4: who just want to lose weight for general health, so

120
00:05:27,600 --> 00:05:30,960
Speaker 4: that's a broad based and then you know products like

121
00:05:31,240 --> 00:05:34,560
Speaker 4: coming like our triple acting Angerton retatritide, which is in

122
00:05:34,600 --> 00:05:38,240
Speaker 4: phase three studies now, will likely be segmented towards more

123
00:05:38,480 --> 00:05:41,040
Speaker 4: the people who need to lose more weight, so their

124
00:05:41,040 --> 00:05:44,120
Speaker 4: BMIs are over thirty five, they have more to lose.

125
00:05:44,800 --> 00:05:47,200
Speaker 4: So I think you'll see new medicines come out covering

126
00:05:47,200 --> 00:05:48,839
Speaker 4: different segments of this very.

127
00:05:48,760 --> 00:05:52,279
Speaker 1: Large and growing market. And the oral likely serves that sort.

128
00:05:52,080 --> 00:05:56,400
Speaker 4: Of first line broad based need and that's great because

129
00:05:56,400 --> 00:05:58,920
Speaker 4: we can produce a lot of it. It also will

130
00:05:58,920 --> 00:06:01,840
Speaker 4: be an important medicine for middle income markets like China

131
00:06:01,920 --> 00:06:05,839
Speaker 4: and Brazil where there is India lots of obesity. But

132
00:06:05,920 --> 00:06:08,760
Speaker 4: we just can't get enough of our product there at

133
00:06:08,800 --> 00:06:10,960
Speaker 4: the right price point right now because the injectible systems

134
00:06:11,000 --> 00:06:12,680
Speaker 4: are expensive and hard to scale.

135
00:06:12,839 --> 00:06:14,920
Speaker 3: Well let's talk a little bit more about pricing here.

136
00:06:14,960 --> 00:06:17,159
Speaker 2: And I know that it's earlier still in trials, but

137
00:06:17,680 --> 00:06:19,880
Speaker 2: if approved, do you expect that the orals would be

138
00:06:19,920 --> 00:06:21,839
Speaker 2: priced cheaper than zet bounds.

139
00:06:22,360 --> 00:06:26,240
Speaker 4: Well, I mean we prices that bound cheaper than semaglutide

140
00:06:26,279 --> 00:06:28,480
Speaker 4: when we launched which and it's a better product. We've

141
00:06:28,520 --> 00:06:33,000
Speaker 4: proven that you lose almost fifty percent more weight when

142
00:06:33,040 --> 00:06:35,520
Speaker 4: we do pricing. Of course, the value in the actual

143
00:06:35,520 --> 00:06:38,160
Speaker 4: clinical data is very important, so we'll have to see that.

144
00:06:38,600 --> 00:06:40,599
Speaker 4: But also we need to think about this segmentation we

145
00:06:40,720 --> 00:06:42,840
Speaker 4: just discussed, So more to come on pricing. We're not

146
00:06:42,839 --> 00:06:45,120
Speaker 4: going to announce it today. We need to first get

147
00:06:45,120 --> 00:06:47,120
Speaker 4: the phase three study done. But our goal will be

148
00:06:47,200 --> 00:06:49,880
Speaker 4: to reach the masses with that product, and so we

149
00:06:49,920 --> 00:06:51,760
Speaker 4: need a price and strategy and concert with that.

150
00:06:52,040 --> 00:06:53,800
Speaker 3: Well, I tried on the pricing, but.

151
00:06:54,120 --> 00:06:55,960
Speaker 1: Welcome back on your show and we'll talk about it.

152
00:06:56,279 --> 00:06:58,360
Speaker 3: I will follow up with you on that. Let's talk

153
00:06:58,360 --> 00:06:59,720
Speaker 3: a little bit about politics here.

154
00:07:00,080 --> 00:07:04,040
Speaker 2: Course, the incoming president Donald Trump, you met with him recently.

155
00:07:04,120 --> 00:07:07,000
Speaker 2: When it comes to the new administration, what sort of

156
00:07:07,120 --> 00:07:10,200
Speaker 2: pricing policies are you potentially anticipating there?

157
00:07:10,840 --> 00:07:12,960
Speaker 1: Yeah, I mean it's a good question.

158
00:07:13,400 --> 00:07:15,920
Speaker 4: We are still waiting for them to be seated, inauguration

159
00:07:16,080 --> 00:07:19,760
Speaker 4: next week and confirmations, etc. I would say first that

160
00:07:20,160 --> 00:07:24,440
Speaker 4: this idea of incoming administration that's focused on the health

161
00:07:24,480 --> 00:07:27,000
Speaker 4: of Americans is one that excites us. And there's a

162
00:07:27,040 --> 00:07:29,520
Speaker 4: lot of common cause with the farmer industry in Lily.

163
00:07:29,840 --> 00:07:32,240
Speaker 4: We wake up every day trying to make America healthy again.

164
00:07:32,320 --> 00:07:35,160
Speaker 4: So if that's the goal, we have common interests how

165
00:07:35,240 --> 00:07:38,760
Speaker 4: that happens. We need to learn more what the strategies are.

166
00:07:39,120 --> 00:07:41,440
Speaker 4: But of course you know, with for instance, with our

167
00:07:41,800 --> 00:07:45,400
Speaker 4: zep bound and what a great tool to really improve

168
00:07:45,400 --> 00:07:46,640
Speaker 4: the overall health of America.

169
00:07:46,760 --> 00:07:48,520
Speaker 1: So we'll seek partnerships with.

170
00:07:48,480 --> 00:07:50,600
Speaker 4: Them to say, how can we expand access, how can

171
00:07:50,640 --> 00:07:53,000
Speaker 4: we get new medicines like or forger prontter proof faster.

172
00:07:53,720 --> 00:07:55,920
Speaker 4: How can we improve insurance coverage and reduce.

173
00:07:55,720 --> 00:07:56,560
Speaker 1: Costs for Americans?

174
00:07:56,600 --> 00:07:59,040
Speaker 4: Those are all, you know, topics we want to engage on,

175
00:07:59,640 --> 00:08:01,480
Speaker 4: and you know, they also want to make the system

176
00:08:01,520 --> 00:08:04,160
Speaker 4: work better. I think the Presence talked about the role

177
00:08:04,200 --> 00:08:07,320
Speaker 4: of the middleman, and of course we need a way

178
00:08:07,360 --> 00:08:09,440
Speaker 4: to get our drugs to patients, but the way the

179
00:08:09,480 --> 00:08:11,480
Speaker 4: systems set up, like so many things in healthcare, is

180
00:08:11,520 --> 00:08:14,480
Speaker 4: too complicated and non transparent, and so we support those

181
00:08:14,560 --> 00:08:15,680
Speaker 4: kinds of changes as well.

182
00:08:16,120 --> 00:08:18,280
Speaker 2: You said, make America healthy again? So I have to

183
00:08:18,280 --> 00:08:20,560
Speaker 2: bring up RFK Junior. Have you met with him?

184
00:08:21,160 --> 00:08:24,080
Speaker 4: He was at the dinner. I think that was widely reported. Yeah, yeah,

185
00:08:24,080 --> 00:08:25,040
Speaker 4: so and we talked about that.

186
00:08:25,080 --> 00:08:26,520
Speaker 1: Where's the common ground? Okay?

187
00:08:26,760 --> 00:08:29,760
Speaker 4: I mean we are focused on people who want to

188
00:08:29,760 --> 00:08:31,760
Speaker 4: get healthy, so we have a lot in common there.

189
00:08:32,360 --> 00:08:33,560
Speaker 3: And I am curious.

190
00:08:33,559 --> 00:08:35,839
Speaker 2: I mean when it comes to specific policies, you mentioned

191
00:08:35,840 --> 00:08:38,120
Speaker 2: this optimism that you have when it comes to the

192
00:08:38,120 --> 00:08:41,720
Speaker 2: inflation Reduction Acts specifically, do you think that Trump will

193
00:08:41,760 --> 00:08:46,040
Speaker 2: finalize that proposal from Biden about the Medicare and negotiations

194
00:08:46,160 --> 00:08:47,880
Speaker 2: or what are your feelings.

195
00:08:47,440 --> 00:08:49,200
Speaker 1: On Well, they've done one round already.

196
00:08:49,280 --> 00:08:51,199
Speaker 4: I mean to our eye, it had all the costs

197
00:08:51,200 --> 00:08:53,400
Speaker 4: and none of the benefits that were promised. So it

198
00:08:53,440 --> 00:08:56,559
Speaker 4: was promised to lower the cost for patients. I don't

199
00:08:56,600 --> 00:08:58,720
Speaker 4: think the new drug pricing will do that at all.

200
00:08:59,000 --> 00:09:02,160
Speaker 4: But in the IRA there were provisions to address the

201
00:09:02,440 --> 00:09:05,960
Speaker 4: way that party benefits are delivered, smoothing costs, capping.

202
00:09:05,640 --> 00:09:06,160
Speaker 1: Out of pocket.

203
00:09:06,160 --> 00:09:08,360
Speaker 4: Those are good things we supported as industry. But the

204
00:09:08,400 --> 00:09:12,880
Speaker 4: idea of the government negotiating drugs directly and then having

205
00:09:13,280 --> 00:09:16,600
Speaker 4: essentially PBMs and other entities implement the program, we think

206
00:09:16,679 --> 00:09:20,480
Speaker 4: is flawed and it won't change value for America or Americans.

207
00:09:20,920 --> 00:09:23,200
Speaker 4: So we're actually going to ask the administration just to

208
00:09:23,240 --> 00:09:26,959
Speaker 4: pause that negoti to the next round of negotiation and

209
00:09:26,360 --> 00:09:29,280
Speaker 4: work make the program work a little better for us.

210
00:09:29,320 --> 00:09:31,760
Speaker 4: It's all about price at the pump when people go

211
00:09:31,800 --> 00:09:34,160
Speaker 4: to the pharmacy counter. How can they have a consistent

212
00:09:34,280 --> 00:09:36,760
Speaker 4: and low cost for benefits that.

213
00:09:36,720 --> 00:09:38,720
Speaker 1: Are helping their health. That's what insurance is for.

214
00:09:39,040 --> 00:09:41,120
Speaker 4: And I'm not sure the construct we just went through

215
00:09:41,880 --> 00:09:43,720
Speaker 4: does that. So there's ways to fix it. We have

216
00:09:43,800 --> 00:09:44,559
Speaker 4: ideas about that.

217
00:09:44,720 --> 00:09:44,840
Speaker 1: Well.

218
00:09:44,880 --> 00:09:47,400
Speaker 2: I appreciate, of course the context there, and I only

219
00:09:47,400 --> 00:09:48,440
Speaker 2: have time for one more question.

220
00:09:48,559 --> 00:09:50,800
Speaker 3: Okay, So I want to go back to Alzheimer's. So

221
00:09:50,800 --> 00:09:52,520
Speaker 3: we were talking a little bit in the commercial.

222
00:09:52,160 --> 00:09:54,320
Speaker 2: Break about it, and you know, in the context of

223
00:09:54,480 --> 00:09:58,559
Speaker 2: Eli Lilly being more than just weight loss drugs. Your

224
00:09:58,600 --> 00:10:02,440
Speaker 2: Alzheimer's treatment received clearance in July of twenty twenty four.

225
00:10:02,840 --> 00:10:05,920
Speaker 2: What indications can you give us about adoption so far?

226
00:10:06,120 --> 00:10:08,120
Speaker 4: Yeah, And it's so exciting for us because we've spent

227
00:10:08,240 --> 00:10:10,320
Speaker 4: so much time, like thirty years working to get a

228
00:10:10,360 --> 00:10:11,200
Speaker 4: medicine approved.

229
00:10:11,360 --> 00:10:12,600
Speaker 1: It's been very difficult.

230
00:10:12,720 --> 00:10:15,199
Speaker 4: We launched in like September we make a number of

231
00:10:15,240 --> 00:10:17,600
Speaker 4: the diagnostics, and the good news is we see a

232
00:10:17,600 --> 00:10:20,560
Speaker 4: lot of people seeking answers to the question if I

233
00:10:20,559 --> 00:10:23,520
Speaker 4: have dementia symptoms, do I also have amyloid? And am

234
00:10:23,520 --> 00:10:26,160
Speaker 4: I a candidate for the medicine? So that's growing pretty

235
00:10:26,280 --> 00:10:29,360
Speaker 4: rapidly right now. And then Cassunla our brand, we're seeing

236
00:10:29,440 --> 00:10:31,520
Speaker 4: utilizations start to ramp, particularly in December.

237
00:10:31,840 --> 00:10:35,000
Speaker 1: So that's good news and we're not done there yet.

238
00:10:35,080 --> 00:10:38,040
Speaker 4: I think there's studies to read out ahead, maybe late

239
00:10:38,080 --> 00:10:41,320
Speaker 4: this year, early next year in Alzheimer's prevention, which is

240
00:10:41,360 --> 00:10:43,640
Speaker 4: I think a much better answer why way too you

241
00:10:43,679 --> 00:10:46,400
Speaker 4: get the dementia symptoms that's prevented if you have amaloid

242
00:10:46,720 --> 00:10:49,920
Speaker 4: excess amyloid in your brain. And then more broadly, I

243
00:10:49,920 --> 00:10:53,760
Speaker 4: think for viewers interesting, I am super bullish on neurodegeneration

244
00:10:54,080 --> 00:10:57,760
Speaker 4: as a category we can address with medicines and what

245
00:10:57,760 --> 00:11:00,760
Speaker 4: are those are the scariest conditions we think about Parkinson's,

246
00:11:00,840 --> 00:11:04,280
Speaker 4: als Alzheimer's. I think there's more medicines coming in Alzheimer's

247
00:11:04,280 --> 00:11:07,760
Speaker 4: and more medicines coming in these other conditions, hopefully from Lily.

248
00:11:08,360 --> 00:11:11,520
Speaker 4: But that's an area where science is moving rapidly and Lily's.

249
00:11:11,160 --> 00:11:11,800
Speaker 1: At the forefront.

250
00:11:12,080 --> 00:11:15,240
Speaker 2: Well, Dave, I so enjoyed this conversation. Hope to speak

251
00:11:15,240 --> 00:11:18,160
Speaker 2: to you again soon. That, of course, is Eli, Lilly's CEO,

252
00:11:18,480 --> 00:11:18,960
Speaker 2: Dave Rix